Cancer
Malignant Ovarian Neoplasm
CI-CAN-00003205Explore in graph →
Top-level684 active trials5 approved drugs83 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00003205Explore in graph →
Clinical trials
3,086 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (437)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00053833 | S0025 Irinotecan in Treating Patients With Refractory Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer | terminated | Phase 2 | 2 | SWOG Cancer Research NetworkNETWORK | 2 | Nov 8, 2013 | clinicaltrials |
| NCT01743547 | The Effects Of Yoga On Quality Of Life Among A Population Of Ovarian/ Fallopian Tube/ Primary Peritoneal Cancer Patients Receiving Chemotherapy: A Feasibility Study | terminated | N/A | 25 | Northwestern UniversityOTHER | 1 | Nov 6, 2013 |
| clinicaltrials |
| NCT01010334 | Comparison of Standard of Care or Treatment on Protocol | terminated | N/A | 13 | New Mexico Cancer Research AllianceOTHER | 1 | Aug 14, 2013 | clinicaltrials |
| NCT01821859 | Abraxane/Bevacizumab | terminated | Phase 2 | 5 | OHSU Knight Cancer InstituteOTHER | 1 | Jul 26, 2013 | clinicaltrials |
| NCT00748527 | Carboplatin With or Without Decitabine in Treating Patients With Progressive, Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | terminated | Phase 2 | 134 | Cancer Research UKOTHER | 1 | Jul 10, 2013 | clinicaltrials |
| NCT00003378 | Combination Chemotherapy in Treating Patients With Previously Untreated Stage III or Stage IV Ovarian or Primary Peritoneal Cancer | terminated | Phase 1 | 45 | Gynecologic Oncology GroupNETWORK | 2 | Jul 9, 2013 | clinicaltrials |
| NCT00084448 | Paclitaxel and Celecoxib in Treating Patients With Recurrent or Persistent Platinum-Resistant Ovarian Epithelial or Primary Peritoneal Cancer | terminated | Phase 2 | — | Gynecologic Oncology GroupNETWORK | 1 | Jul 9, 2013 | clinicaltrials |
| NCT00002478 | Etoposide in Treating Patients With Advanced Ovarian or Cervical Cancer | terminated | Phase 2 | — | Gynecologic Oncology GroupNETWORK | 1 | Jun 10, 2013 | clinicaltrials |
| NCT00003380 | Liposomal Doxorubicin and Etoposide in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, or Peritoneal Cancer | terminated | Phase 1 | — | Gynecologic Oncology GroupNETWORK | 2 | Jun 10, 2013 | clinicaltrials |
| NCT00003382 | Combination Chemotherapy Consisting of Gemcitabine And Topotecan in Treating Patients With Refractory or Recurrent Ovarian or Fallopian Tube Cancer | terminated | Phase 1 | — | Gynecologic Oncology GroupNETWORK | 1 | Jun 10, 2013 | clinicaltrials |
| NCT00003794 | Quality-of-Life Study of Patients With Previously Treated Ovarian Cancer | terminated | — | — | Gynecologic Oncology GroupNETWORK | 1 | Jun 10, 2013 | clinicaltrials |
| NCT00017134 | Fenretinide Followed by Surgery Compared With Surgery Alone in Preventing Ovarian Cancer in Patients at Increased Risk | terminated | N/A | 71 | Gynecologic Oncology GroupNETWORK | 1 | Jun 10, 2013 | clinicaltrials |
| NCT00583622 | Bevacizumab Plus Gemcitabine, Docetaxel, Melphalan, and Carboplatin in Ovarian Cancer Patients | terminated | Phase 2 | 13 | M.D. Anderson Cancer CenterOTHER | 1 | May 21, 2013 | clinicaltrials |
| NCT01383408 | Distinction Between Lung Cancer and Gynecological Cancers by Canine Scent Detection | terminated | Phase 2 | 752 | Schillerhoehe HospitalOTHER | 1 | May 7, 2013 | clinicaltrials |
| NCT00002819 | Chemotherapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Persistent Ovarian Epithelial Cancer | terminated | Phase 3 | — | Gynecologic Oncology GroupNETWORK | 1 | Apr 11, 2013 | clinicaltrials |
| NCT00003386 | Vaccine Therapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer | terminated | Phase 2 | — | Gynecologic Oncology GroupNETWORK | 2 | Apr 11, 2013 | clinicaltrials |
| NCT00003624 | Amifostine in Treating Women With Ovarian, Peritoneal, Cervical, Fallopian Tube, Uterine, or Endometrial Cancer | terminated | Phase 2 | — | Gynecologic Oncology GroupNETWORK | 1 | Apr 11, 2013 | clinicaltrials |
| NCT00004037 | Docetaxel in Treating Patients With Recurrent or Refractory Ovarian or Primary Peritoneal Cancer | terminated | Phase 2 | — | Gynecologic Oncology GroupNETWORK | 2 | Apr 11, 2013 | clinicaltrials |
| NCT00006812 | Capecitabine in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cavity Cancer | terminated | Phase 2 | — | Gynecologic Oncology GroupNETWORK | 2 | Apr 11, 2013 | clinicaltrials |
| NCT00023907 | Paclitaxel in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer | terminated | Phase 2 | — | Gynecologic Oncology GroupNETWORK | 1 | Apr 11, 2013 | clinicaltrials |
| NCT00091195 | Depsipeptide (Romidepsin) in Treating Patients With Recurrent Ovarian Epithelial or Peritoneal Cavity Cancer | terminated | Phase 2 | 51 | National Cancer Institute (NCI)NIH | 1 | Mar 19, 2013 | clinicaltrials |
| NCT01016054 | A Study of the Safety and Pharmacokinetics of AGS-8M4 Given in Combination With Chemotherapy in Women With Ovarian Cancer | terminated | Phase 1 | 4 | Astellas Pharma IncINDUSTRY | 1 | Feb 27, 2013 | clinicaltrials |
| NCT00523809 | Allogeneic Hematopoietic Stem Cell Transplantation With Bevacizumab for Advanced Solid Tumor | terminated | Phase 2 | 5 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 28, 2013 | clinicaltrials |
| NCT00042952 | Imatinib Mesylate in Treating Patients With Progressive, Refractory, or Recurrent Stage II or Stage III Testicular or Ovarian Cancer | terminated | Phase 2 | 32 | National Cancer Institute (NCI)NIH | 1 | Jan 17, 2013 | clinicaltrials |
| NCT00087191 | EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer | terminated | N/A | 30 | National Cancer Institute (NCI)NIH | 1 | Jan 16, 2013 | clinicaltrials |
| NCT00840450 | Imatinib Mesylate (Gleevec) and Paclitaxel in Recurrent Patients of Ovarian and Other Cancers of Mullerian Origin | terminated | Phase 2 | 14 | NYU Langone HealthOTHER | 1 | Nov 19, 2012 | clinicaltrials |
| NCT01177501 | Trial of High Dose Topotecan With Carboplatin in Patients With Relapsed Ovarian Carcinoma(ITOV04) | terminated | Phase 1 | 3 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Nov 19, 2012 | clinicaltrials |
| NCT00288275 | Correlation of the Chemoresponse Assay With PFS in Patients With Recurrent Epithelial Ovarian, Peritoneal, or Fallopian Tube Cancer | terminated | — | 256 | Precision TherapeuticsINDUSTRY | 1 | Oct 5, 2012 | clinicaltrials |
| NCT00669422 | ChemoFx® PRO - A Post-Market Data Collection Study | terminated | — | 2,756 | Precision TherapeuticsINDUSTRY | 1 | Oct 5, 2012 | clinicaltrials |
| NCT00005612 | Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Ovarian Epithelial Cancer(ETC) | terminated | Phase 1 / Phase 2 | 3 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Sep 26, 2012 | clinicaltrials |
| NCT00006356 | Chemotherapy With or Without Surgery in Treating Patients With Recurrent Ovarian Cancer | terminated | Phase 3 | 38 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 1 | Sep 24, 2012 | clinicaltrials |
| NCT00516841 | A Phase 2, Single-Arm Study of Volociximab Monotherapy in Subjects With Platinum-Resistant Advanced Epithelial Ovarian Cancer or Primary Peritoneal Cancer | terminated | Phase 2 | 16 | Facet BiotechINDUSTRY | 2 | Aug 23, 2012 | clinicaltrials |
| NCT00085384 | PEG-Interferon Alfa-2b in Treating Patients With Platinum-Resistant Ovarian Epithelial, Peritoneal, or Fallopian Tube Cancer | terminated | Phase 1 / Phase 2 | 30 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 2, 2012 | clinicaltrials |
| NCT00897806 | Identifying Genetic Markers That Predict Response to Paclitaxel in Patients With Newly Diagnosed Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer | terminated | — | 7 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 30, 2012 | clinicaltrials |
| NCT00006262 | Rebeccamycin Analogue in Treating Patients With Refractory Stage III or Stage IV Ovarian Epithelial Cancer | terminated | Phase 2 | — | Northwestern UniversityOTHER | 1 | Jun 11, 2012 | clinicaltrials |
| NCT00653328 | Ph II Atrasentan + DOXIL in Recurrent Ovarian/Fallopian/Peritoneal Serous Papillary Adenocarcinoma | terminated | Phase 2 | 15 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | May 23, 2012 | clinicaltrials |
| NCT00505661 | Letrozole in Patients With Ovarian Tumors | terminated | Phase 2 | 16 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 18, 2012 | clinicaltrials |
| NCT00253461 | 11C Topotecan PET Imaging | terminated | Early Phase 1 | 7 | Case Comprehensive Cancer CenterOTHER | 1 | Mar 20, 2012 | clinicaltrials |
| NCT01212887 | Treated Blood Cells, Cyclophosphamide, Fludarabine Phosphate, and Aldesleukin in Treating Patients With Cancer | terminated | Phase 1 | 14 | Cancer Research UKOTHER | 1 | Feb 28, 2012 | clinicaltrials |
| NCT01096381 | Potential Biomarkers for Bevacizumab-Induced High Blood Pressure in Patients With Solid Tumor | terminated | — | 8 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Feb 27, 2012 | clinicaltrials |
| NCT00418574 | Efficacy Multicentre Trial of ImmunoTherapy Vaccination With Abagovomab to Treat Ovarian Cancer Patients(MIMOSA) | terminated | Phase 2 / Phase 3 | 888 | Menarini GroupINDUSTRY | 9 | Nov 24, 2011 | clinicaltrials |
| NCT00926107 | Study of the mTOR Inhibitor Temsirolimus (CCI-779) to Treat Ovarian Cancer With CA125 Only Relapse | terminated | Phase 2 | 9 | Hellenic Cooperative Oncology GroupOTHER | 1 | Nov 10, 2011 | clinicaltrials |
| NCT00898781 | Study of Circulating Cancer Cells in Patients With Metastatic Breast, Ovarian, Colon, or Pancreatic Cancer | terminated | — | 80 | Mayo ClinicOTHER | 1 | Jul 19, 2011 | clinicaltrials |
| NCT00531778 | NYU Ovarian Cancer Early Detection Program Blood and Genetics | terminated | — | 890 | NYU Langone HealthOTHER | 1 | Jan 11, 2011 | clinicaltrials |
| NCT00082212 | A Study in Patients With Persistent or Recurrent Epithelial Ovarian or Primary Peritoneal Carcinoma | terminated | Phase 2 | 25 | Eli Lilly and CompanyINDUSTRY | 1 | Apr 9, 2010 | clinicaltrials |
| NCT00277290 | Study of XL999 in Patients With Previously Treated Ovarian Cancer | terminated | Phase 2 | 24 | Symphony Evolution, Inc.INDUSTRY | 1 | Feb 22, 2010 | clinicaltrials |
| NCT00317434 | Maximum Tolerated Dose of Lapatinib When Given With Carboplatin for Recurrent Ovarian Cancer | terminated | Phase 1 | 12 | University of Alabama at BirminghamOTHER | 1 | Dec 15, 2009 | clinicaltrials |
| NCT00050375 | Clinical Trial for Ovarian Cancer (OvaRex®) | terminated | Phase 3 | 354 | Unither PharmaceuticalsINDUSTRY | 1 | Dec 18, 2007 | clinicaltrials |
| NCT00086632 | Study of Ovarex® (Oregovomab) MAb With Front-Line Chemotherapy for Ovarian Cancer Treatment | terminated | Phase 2 | 40 | Unither PharmaceuticalsINDUSTRY | 0 | Dec 18, 2007 | clinicaltrials |
| NCT00047632 | Safety and Efficacy of Interferon Gamma-1b Plus Chemotherapy for Ovarian and Peritoneal Cancer | terminated | Phase 3 | 847 | InterMuneINDUSTRY | 1 | Nov 1, 2007 | clinicaltrials |
Data updated 23 days agoSource updated Nov 8, 2013source: clinicaltrials